FDA Advisory Committee Unanimously Recommends First mRNA Flu Vaccine

On June 18, 2026, the FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) delivered a historic 9-0 vote recommending the approval of Moderna's mRNA-based seasonal influenza vaccine.[1][4]

The unanimous endorsement of the vaccine, known clinically as mRNA-1010 or mFlusiva, marks a critical milestone in respiratory health. If granted final approval, it will be the first time the Nobel Prize-winning technology that ended the COVID-19 pandemic is deployed against seasonal flu.[2][6]

The core claim evaluated by the committee is that mRNA technology provides superior efficacy to traditional egg-based vaccines. The evidence supporting this primary claim is robust, anchored by the Phase 3 FLUENT trial.[3][5]

The FLUENT trial enrolled 40,703 participants aged 50 and older across 11 countries during the recent flu season. It was designed as a double-blind, active-controlled study to directly compare the mRNA shot against existing options.[3][6]

The data demonstrated that mRNA-1010 achieved a 26.6% relative vaccine efficacy against protocol-defined influenza-like illness when compared to a licensed standard-dose vaccine.[4][5]

Beyond raw efficacy, the evidence pack highlights a massive logistical advantage: the speed of manufacturing. Traditional flu vaccines require a cumbersome, egg-based incubation process that takes roughly six months.[1][6]

Because of this six-month lag, global health agencies are forced to guess which flu strains will circulate in the fall as early as February. If the virus mutates in the intervening months, the resulting vaccine can be a poor match, leading to severe flu seasons.[2][6]

The mRNA platform shrinks this strain-to-shot timeline to just two to three months. This rapid turnaround drastically reduces the risk of antigenic drift, allowing scientists to formulate the shot much closer to the actual respiratory season.[1][4]

Immunological evidence also suggests that the mRNA platform expands the breadth of the B-cell response. Trial data indicates the vaccine produces antibodies capable of recognizing a wider array of flu strains than traditional platforms.[5][6]

However, the evidence pack reveals a notable weakness regarding older adults, sparking a fierce regulatory debate over the trial's design.[4][6]

For patients aged 65 and older, the standard of care is typically a high-dose or adjuvanted flu vaccine designed specifically to provoke a stronger immune response in aging immune systems.[2][4]

Moderna's pivotal trial compared the mRNA vaccine against a standard-dose shot across all age groups, rather than testing it head-to-head against the high-dose vaccines recommended for seniors.[3][4]

This evidentiary gap led to intense regulatory friction. In February 2026, the FDA initially issued a refusal-to-file letter, declining to even review the application because of the comparator issue.[1][6]

The rejection occurred during a period of heightened political scrutiny regarding vaccine research, driven by skepticism toward mRNA technology from HHS Secretary Robert F. Kennedy Jr. and former FDA officials.[1][2]

Following public backlash from the medical community and a formal meeting with the manufacturer, the FDA reversed its refusal and agreed to evaluate the data under a bifurcated regulatory pathway.[2][6]

To bridge the evidentiary gap, the advisory committee recommended full approval for adults aged 50 to 64, where standard-dose vaccines are the accepted baseline.[4][5]

For adults 65 and older, the committee recommended an accelerated approval pathway. This requires Moderna to conduct a massive post-marketing confirmatory trial—enrolling up to 800,000 participants over two flu seasons—to test the mRNA shot directly against high-dose senior vaccines.[4][6]

On the safety front, the evidence is clear but comes with trade-offs. The FDA briefing documents confirmed no major safety deficiencies, noting that the mRNA does not enter the cellular nucleus or alter DNA.[4][5]

However, the clinical data shows higher reactogenicity. Patients receiving the mRNA shot reported higher rates of temporary side effects, including injection-site pain (65.8%), fatigue (45.1%), and headaches (37.8%), though these were predominantly mild and self-limiting.[3][4]

The FDA has set a final decision deadline of August 5, 2026. If the agency follows the committee's unanimous recommendation, the medical community will have a powerful, rapidly adaptable new tool available for the upcoming fall respiratory season.[1][2]